BELTSVILLE, Md.--(BUSINESS WIRE)--NextCure, Inc. today announced the appointment of Kevin N. Heller, M.D., as Chief Medical Officer and Steve Cobourn, CPA, as Chief Financial Officer.
“We are delighted to welcome Kevin and Steve to NextCure,” stated Michael Richman, NextCure’s President & CEO. “Both are accomplished executives with proven track records in building biopharmaceutical companies.”
“Kevin’s experience in clinical development of novel immune checkpoint therapeutics will provide great value to NextCure as we enter the clinic later this year with NC318, a first-in-class candidate,” added Mr. Richman. “Steve brings significant expertise in financial management of biopharmaceutical companies and his leadership will be invaluble to NextCure.”
Most recently Dr. Heller was Vice President, Head of mAb Clinical Development, Immuno-Oncology at Incyte Corporation where he led the clinical development of Incyte’s monoclonal antibody programs for cancer immunotherapy. He was also Chair of Incyte’s Immunotherapy Strategy Team. Prior to joining Incyte, Dr. Heller was the Senior Medical Director for Oncology at AstraZeneca where he led late stage clinical development programs. Dr. Heller also held various positions at Bristol-Myers Squibb (BMS) where he was Director, US Medical Lead for Ipilimumab and Global Lead, Oncology, Strategic Transactions Group. He received his M.D. from George Washington University and B.S. in Molecular Biophysics & Biochemistry from Yale University.
Mr. Cobourn has more than 20 years of experience in life sciences including financing, product launches, alliances, and operations. Previously, he was the Chief Financial Officer of Vaccinex, Inc., a privately held clinical-stage biotechnology company. Prior to joining Vaccinex, Mr. Cobourn was Vice President of Finance, Treasurer, and Corporate Officer of Otsuka America Pharmaceutical, Inc., the U.S. division of publicly traded Otsuka Holdings Co., Ltd. During his tenure, he participated in overseeing the growth of revenue from Otsuka’s U.S. operations from $10 million to $5 billion. He received his B.S. in Business Administration from Drexel University and is a Certified Public Accountant in the State of Pennsylvania.
About NextCure, Inc.
NextCure is a biopharmaceutical company focused on discovering and developing next generation first-in-class immunotherapy-based biologics for cancer and other diseases. The company leverages its FIND-IOTM technology to discover, validate and build a proprietary pipeline of novel immunotherapy targets.
NC318 is a first-in-class immunotherapeutic directed against a novel target found on myeloid cells and tumor cells. NC318 prevents the formation and survival of suppressive myeloid cells and blocks the suppressive function of macrophages, leading to increased T cell function and anti-tumor immunity. NextCure is initially moving NC318 forward for the treatment of solid cancers and plans to file an IND in 3Q 2018.
Please visit www.nextcure.com for more information.